The goal of this clinical trial is to find out if the investigational medicine BMS-986353 is safe and well tolerated in adults with anti-aquaporin-4 (AQP4) ant…

AQP4+ NMOSD

~Estimated

~$10 – $6,250

University of Texas Southwestern Medical CenterNCT07573332

A Long-Term, Prospective, Observational, Registry of Patients With Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated With Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)

Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in…

Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD

~Estimated

~$10 – $1,050

Alexion Pharmaceuticals, Inc.NCT05966467